Real‐World Data of Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients With Rheumatoid Arthritis From a Drug‐Based Cohort Study
International Journal of Rheumatic Diseases · 2026
DOI: 10.1111/1756-185x.70653 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Rheumatic Diseases, 2026. Verfasst von Song-Chou Hsieh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Immunology and Allergy, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Piperidines, Pyrimidines, Janus Kinase Inhibitors. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Aim
To assess the long‐term effectiveness and safety of, and persistence/adherence to, tofacitinib (an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis [RA]) and tumor necrosis factor inhibitors (TNFi) in Taiwanese patients with RA in real‐world settings.
Methods
This was a 5 year, prospective cohort study in Taiwanese patients with RA newly initiating tofacitinib or TNFi. Patients received standard care per treating rheumatologists and fulfillment of National Health Insurance reimbursement criteria. Effectiveness outcomes (baseline and every 24 weeks) included: Disease Activity Score in 28 joints, erythrocyte sedimentation rate; Clinical Disease Activity Index; Health Assessment Questionnaire‐Disability Index; and Work Productivity and Activity Impairment‐RA. Differences between groups were compared using mixed logistic regression models. Safety and persistence/adherence were assessed throughout.
Results
In total, 267 patients were included (tofacitinib, n = 145; TNFi, n = 122). No significant differences in effectiveness outcomes for tofacitinib versus TNFi were reported before or after propensity score adjustment. In patients receiving tofacitinib and TNFi, rates of adverse events (AEs; 56.6% vs. 55.7%), serious AEs (20.0% vs. 21.3%), major adverse cardiovascular events (0% vs. 0.8%), malignancy (2.1% vs. 0.8%), and deaths (1.4% vs. 3.3%) were similar. Serious infections/herpes zoster occurred in 13.1%/12.4% and 8.2%/3.3% of patients receiving tofacitinib and TNFi, respectively. No venous thromboembolism events were reported. Persistence/adherence was comparable between tofacitinib and TNFi.
Conclusion
Tofacitinib effectiveness and persistence/adherence were generally similar to TNFi in this real‐world analysis in Taiwanese patients with RA. Safety outcomes were consistent with the known safety profiles of tofacitinib and TNFi. Trail Registration EUPAS13431.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Immunology and Allergy, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Medicine, National Taiwan University Cancer Center, National Taiwan University College of Medicine, Taipei, Taiwan.
- Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
- Faculty of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Division of Allergy, Immunology and Rheumatology, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
- Department of Allergy, Immunology, and Rheumatology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
ORCID-Profile: Wan-Yu Sung
Förderung
- Pfizer
Zitieren
APA
Hsieh, S. C., Chen, W. S., Hu, J. C., Sung, W. Y., Tsai, W. C., Chen, H. C., Huang, C. M., Kuo, E., Gruben, D., & Chen, Y. H. (2026). Real‐World Data of Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients With Rheumatoid Arthritis From a Drug‐Based Cohort Study. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.70653
Vancouver
Hsieh SC, Chen WS, Hu JC, Sung WY, Tsai WC, Chen HC, et al. Real‐World Data of Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients With Rheumatoid Arthritis From a Drug‐Based Cohort Study. International Journal of Rheumatic Diseases. 2026. doi:10.1111/1756-185x.70653
BibTeX
@article{Hsieh2026,
author = {Hsieh, Song-Chou and Chen, Wei-Sheng and Hu, Jui-Chieh and Sung, Wan-Yu and Tsai, Wen-Chan and Chen, Hsiang-Cheng and Huang, Chung-Ming and Kuo, Edward and Gruben, David and Chen, Yi-Hsing},
title = {Real‐World Data of Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients With Rheumatoid Arthritis From a Drug‐Based Cohort Study},
journal = {International Journal of Rheumatic Diseases},
year = {2026},
doi = {10.1111/1756-185x.70653}
}
EUVIMED